Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Consensus Rating of "Buy" from Brokerages

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) have earned an average rating of "Buy" from the thirteen research firms that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $49.91.

Several analysts have weighed in on the company. Chardan Capital reaffirmed a "buy" rating and set a $50.00 price objective on shares of Dyne Therapeutics in a research report on Friday, January 10th. HC Wainwright reissued a "buy" rating and issued a $55.00 price target on shares of Dyne Therapeutics in a research report on Friday, January 10th. Royal Bank of Canada reissued an "outperform" rating and issued a $45.00 price target on shares of Dyne Therapeutics in a research report on Tuesday, January 14th. Robert W. Baird assumed coverage on Dyne Therapeutics in a research report on Friday, December 13th. They issued an "outperform" rating and a $46.00 price target on the stock. Finally, Guggenheim reissued a "buy" rating on shares of Dyne Therapeutics in a research report on Friday, January 24th.

Dyne Therapeutics Price Performance

NASDAQ:DYN traded up $0.02 during mid-day trading on Tuesday, reaching $14.01. 1,166,163 shares of the company's stock traded hands, compared to its average volume of 2,323,284. Dyne Therapeutics has a 12-month low of $13.07 and a 12-month high of $47.45. The firm has a market capitalization of $1.43 billion, a price-to-earnings ratio of -3.94 and a beta of 1.11. The company has a 50 day moving average price of $18.36 and a 200-day moving average price of $28.94.

Remove Ads

Insider Buying and Selling at Dyne Therapeutics

In other Dyne Therapeutics news, SVP Richard William Scalzo sold 1,455 shares of the business's stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total transaction of $40,914.60. Following the completion of the sale, the senior vice president now directly owns 127,078 shares in the company, valued at approximately $3,573,433.36. The trade was a 1.13 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Oxana Beskrovnaya sold 2,334 shares of the company's stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total value of $65,632.08. Following the completion of the sale, the insider now owns 201,685 shares of the company's stock, valued at $5,671,382.20. This trade represents a 1.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 20.77% of the company's stock.

Institutional Investors Weigh In On Dyne Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. FMR LLC increased its stake in shares of Dyne Therapeutics by 69.7% in the 3rd quarter. FMR LLC now owns 9,026,697 shares of the company's stock worth $324,239,000 after purchasing an additional 3,707,734 shares in the last quarter. Janus Henderson Group PLC increased its stake in shares of Dyne Therapeutics by 8.3% in the 4th quarter. Janus Henderson Group PLC now owns 7,379,309 shares of the company's stock worth $173,808,000 after purchasing an additional 566,146 shares in the last quarter. RTW Investments LP increased its stake in shares of Dyne Therapeutics by 6.8% in the 3rd quarter. RTW Investments LP now owns 6,818,641 shares of the company's stock worth $244,926,000 after purchasing an additional 431,503 shares in the last quarter. RA Capital Management L.P. increased its stake in shares of Dyne Therapeutics by 5.5% in the 3rd quarter. RA Capital Management L.P. now owns 6,381,144 shares of the company's stock worth $229,211,000 after purchasing an additional 331,940 shares in the last quarter. Finally, State Street Corp increased its stake in shares of Dyne Therapeutics by 13.8% in the 3rd quarter. State Street Corp now owns 3,641,859 shares of the company's stock worth $130,816,000 after purchasing an additional 440,890 shares in the last quarter. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.